Benjamin Cravatt

Sea Pharmaceuticals LLC manufactures and markets pharmaceutical products and services. The company is headquartered in Cambridge, MA.

Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA.

The National Academy of Inventors operates as a business association that promotes investors. The private company is based in Tampa.

Autobahn Therapeutics, Inc. is a thyromimetics drug discovery company. It serves patients with neurodegenerative disorders. The company is headquartered in San Diego, CA.

Kisbee Therapeutics, Inc develops novel therapeutic agents for neurodegenerative diseases. The company was founded by Benjamin Cravatt, Jennifer Lippincott Schwartz, Emily Ricqu and Stuart L.Schreiber and is headquartered in DE.

Kojin Therapeutics, Inc. operates as a small-molecule therapeutics company. It focuses on translating deep biological insight into the plasticity of human cell states to develop therapeutics for cancer, fibrosis, ischemia and immune modulation. The company was founded by Benjamin Cravatt, Stephanie K. Dougan and Stuart L.Schreiber and is headquartered in the United States.

Magnet Biomedicine, Inc. is a biotechnology company based in Cambridge, MA. Magnet Biomedicine is advancing molecular glue discovery with rational selection and design through their TrueGlue discovery platform. The company applies cutting-edge advancements in human biology and proteomics to identify fit-for-purpose glues that maximize therapeutic impact and offer prominent benefits such as improving selectivity, inducing biological synergy on defined targets, and addressing historically undruggable proteins. Magnet Biomedicine is revolutionizing human medicine with molecular glues and is tackling multiple disease areas and biological mechanisms, including cancer, cardiovascular disease, and immune disorders. The company was founded by Benjamin F. Cravatt, Stuart L. Schreiber, Michael Rosbash, Richa Saxena.

Belharra Therapeutics, Inc. is a drug discovery company that utilizes a unique photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously difficult-to-treat diseases and conditions. The company is based in San Diego, CA, with its primary lab and offices located in the area. Belharra's proprietary discovery engine allows for the identification of small molecule starting points for drug development on any protein, in any conformational state, and in any cell type. The company was founded in 2021 by John Teijaro, Christopher G. Parker, Stuart L. Schreiber, and Benjamin F. Cravatt, and has since been led by CEO Jeffrey Jonker.